Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Phase I Study Of Medi-534 Of A Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus And Parainfluenza-3 Virus In Seropositive Children, Margarita Gomez, Maurice A. Mufson, Filip Dubovsky, Conor Knightly, Wen Zeng, Genevieve Losonsky
Phase I Study Of Medi-534 Of A Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus And Parainfluenza-3 Virus In Seropositive Children, Margarita Gomez, Maurice A. Mufson, Filip Dubovsky, Conor Knightly, Wen Zeng, Genevieve Losonsky
Internal Medicine
A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 104, 105 or 106 median tissue culture infectious dose50 MEDI-534 vaccine of placebo. The vaccine's safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic.